PharmaDrug receives encouraging potency data for candidate DMT-analogue molecules designed to treat primary open angle glaucoma Terasaki Institute advances PharmaDrug’s candidate DMT-analogue molecules into next phase...
Patent claims on synergistic application of cepharanthine, cabazitaxel and other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer Expands on...
Establishing cGMP supply for IND-enabling and up to Phase 2 clinical studies for PD-001 oral formulation for esophageal cancer and mild to moderate COVID-19 Toronto, Ontario–(Newsfile...
Toronto, Ontario–(Newsfile Corp. – January 24, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on...